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Introduction 
The metabolic syndrome (MetS) is characterized by clusters of metabolic 
risk factors (1), which might increase cardiovascular (CV) risk beyond what is 
predicted by single components (2-5). The MetS is associated with increased 
risk of cardiac mortality also in the absence of diabetes and independently of 
arterial hypertension (6-8). It has been previously reported that MetS is 
related to abnormal left ventricular (LV) geometry and function in non 
diabetic adults with high prevalence of obesity, and that increased blood 
pressure is the component of MetS most strongly associated with markers of 
pre-clinical CV disease even in the absence of traditionally defined 
hypertension (9).  
The rising prevalence of obesity and hypertension among children and 
adolescents is now a major health concern with both epidemiological and 
economic implications (9-11). We have already reported that LV hypertrophy 
can be found in 30 percent of obese adolescents at mean age<18 years, 
despite a low prevalence of hypertension (13). And it has also been observed 
that obese adolescents often have MetS, suggesting that the increased LV 
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mass might be a response not only to increased hemodynamic load but also 
to possible neurohormonal effects of clustered metabolic factors influencing 
LV growth (13). To date, little information is available on whether the 
presence of MetS is associated with significant cardiac abnormalities in 
adolescents, or whether the impact of MetS on cardiac phenotype is 
independent of the single components of the syndrome. Accordingly the 
present analysis has been designed to study the CV effects of MetS in 
adolescents from a population-based sample. 
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METHODS 
Study population.  
The Strong Heart Study (SHS) is a longitudinal study of CV risk factors 
and prevalent and incident CV disease in American Indian communities in 
Arizona, Oklahoma, and North/South Dakota.  As previously described (14), 
4,549 members of 13 tribes age 45 to 74 years were recruited from defined 
sampling frames (overall participation rate>61%) for baseline examination in 
July 1989 to January 1992. The 4th SHS examination (13), conducted in 2001 
to 2003, enrolled members of large three-generation families that included a 
total of 460 adolescent participants (age<20 years, mean 17.3±1.5 years; 
53.2% female). After excluding participants with ADA-defined diabetes 
(N=10) and/or significant valvular disease (N=4), 446 adolescents (14-20 
years of age) were included in the present analysis. 
  
Physical examination and laboratory testing. 
 The examination included medical history, computerized 
electrocardiogram, measurement of brachial blood pressure, fasting glucose 
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and insulin, glycated hemoglobin, lipid and lipoprotein levels, and a 2-h, 75-g 
glucose tolerance test (15). Blood pressure was measured as recommended 
by the Fifth Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (15). Laboratory tests and 
anthropometric measures (weight, height, and waist circumferences) were 
taken as previously reported (16). Fat-free mass and adipose body mass 
were estimated by the use of an RJL impedance meter (model B14101, RJL 
Equipment Co., Clinton Township, Missouri) and equations based on total 
body water validated in the American Indian population (17). 
  
Definition of obesity, hypertension, and metabolic syndrome. 
As recommended, 95th percentiles of body mass index (BMI)-for-age 
charts developed by the National Center for Health Statistics (18), were used 
to define obesity. Guidelines correction was applied (19) so that the limit 
separating overweight and obesity did not exceed a BMI of 30 kg/m2.  
For adolescents up to 18 years of age, hypertension was assessed by 
using age-, gender-, and height specific partition values according to the 
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Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood 
Pressure in Children and Adolescents (20). For adolescents over 18 years of 
age, recommendations from the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure were followed (21). MetS was preliminary identified using 
adult ATPIII (22) definition (with partition value of 100mg/dL for fasting 
glucose), and then applying the ATPIII modified definition developed by 
Jolliffe and Janssen for adolescents (23). Accordingly, diagnosis of MetS was 
made when at least three of the five components of the syndrome (increased 
waist circumference, high blood pressure, high triglycerides, high fasting 
glucose and low HDL-C) were present, applying age- and gender- specific 
partition values (see Appendix 1). 
 
Echocardiography.  
Echocardiograms were performed by expert sonographers, according to 
standardized methods and reviewed off-line by two independent readers (MC, 
RBD) using computerized review station with digitizing tablet and monitor 
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screen overlay for calibration and performance of needed measurements 
(25). Left ventricular internal dimension, septal and posterior wall thickness 
were measured at end-diastole and end-systole by American Society of 
Echocardiography recommendations on three cycles (26,27). As previously 
described (28), left atrial (LA) anteroposterior diameter was measured in 
long-axis view in end-systole, and aortic root diameter was measured at level 
of the sinus of Valsalva in end-diastole.  Since normal LA size in children 
increases with growth (29), LA diameter was normalized for body height to 
account for differences in body maturation. Partition values for the definition 
of LA dilatation were 2.23 cm/m in boys and 2.11 cm/m in girls, representing 
age-, gender- and ethnic-specific 95th percentiles derived in a subgroup of 92 
normal adolescent participants. A necropsy-validated formula was used to 
calculate LV mass (30), which was normalized for body height in meters to 
the allometric power of 2.7, which linearizes the relations between LV mass 
and height (i.e. body growth) and identifies the impact of excess body weight 
(31). Partition values for the definition of LV hypertrophy were 40.75 g/m2.7 
for boys and 38.49 g/m2.7 for girls, representing previously reported age-, 
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gender- and ethnic-specific cut-off points (13). To evaluate the concentricity 
of LV geometry, myocardial thickness (wall + septum) was divided by LV 
minor axis (diameter) to generate a relative wall thickness (RWT). Because 
normal RWT increases with age (32), its raw value was adjusted for age 
(RWTa) by previously reported equations (32). LV systolic performance was 
assessed by LV ejection fraction, and by LV shortening measured at the mid-
wall level (midwall shortening) (33). Stroke volume was determined by an 
invasively-validated Doppler method (34) and used to calculate cardiac 
output.  
Left ventricular diastolic properties were assessed by Doppler 
interrogation of transmitral peak early (E) and late (A) velocities and by 
measurement of the deceleration time of peak E velocity. Isovolumic 
relaxation time was measured between mitral valve closure and aortic valve 
opening. 
 
Statistical analysis. 
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  Statistical analyses were performed using SPSS 12.0.0 (SPSS Inc., 
Chicago, Illinois) software. Data are presented as mean±SD for continuous 
variables and as proportions for categorical variables. Descriptive statistics 
were based on normal or χ2 distributions. Population was dichotomized 
according to the presence of MetS. Comparison of demographics and 
laboratory tests was performed by independent t-test. Comparison of cardiac 
geometry and function was performed by analysis of covariance (ANCOVA) 
correcting for differences in age, gender, heart rate and body height 
(considered as an estimate of body maturation at a given age and gender). 
In addition, binary logistic multiple regression modeling was performed, 
controlling for confounders (age and gender), with the specific aim of 
determining whether clustered MetS confers additional and independent risk 
of presenting markers of preclinical cardiovascular disease (i.e. LV 
hypertrophy and LA dilatation) as compared to single risk factors. Covariates 
were entered in the model using a hierarchical enter procedure in the 
following order: 1) age and gender; 2) presence of obesity; 3) systolic blood 
pressure 4) single metabolic components of MetS (including fasting glucose, 
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HDL-C and Triglycerides); 5) presence of MetS. Alternative models were also 
performed replacing obesity with waist circumference, and fasting glucose 
with either plasma insulin or HOMA-index.  
 
Results 
Distribution of Risk Factors.  
Adult ATPIII criteria for the definition of MetS, identified 71 participants 
with the syndrome (15.9% of population, 53.5% girls). According to the 
adolescent criteria, MetS was instead present in 111 participants (24.9% of 
population, 55.9% girls; Kappa Score between criteria=0.66) with similar 
prevalence in women (26.3%) and men (23.3%; p=ns). The most prevalent 
component of the MetS in the studied population was increased waist 
circumference (54.3%), followed by low HDL cholesterol (46.4%), high blood 
pressure (30.3%), increased serum triglycerides (27.8%), and increased 
fasting glucose (2.5%). Of the 446 participants, 102 (22.9%) had no 
component of the MetS, 116 (26%) had only one risk factor, 117 (26.2%) 
  12
had two clustered risk factors, 77 (17.3%)  had  three, 32 (7.2%)  had  four, 
and only 2 participants (0.4%) showed clustered presence of all five.  
 
Clinical and laboratory characteristics of the population by MetS class. 
Participants with Mets had similar age, gender distribution and heart rate, 
compared to non-MetS (Table 1). Comparison of antropometrics, body 
composition and laboratory tests identified the expected unfavorable 
phenotype in the MetS participants as opposed to non-MetS, characterized by 
higher fat and fat-free body mass, higher BMI and higher blood pressure 
values. Prevalences of obesity and hypertension were also significantly higher 
in MetS participants (both p<0.001). Similar prevalence of smoking habit and 
alcohol drinking were observed between the two groups (p=ns).  
Metabolic characteristics of the study population are shown in table 2. As 
expected, participants with the MetS showed worse glicemic profile (higher 
fasting glucose, insulin, and HOMA index), worse lipid profile (higher total 
cholesterol, LDL cholesterol and triglycerides and lower HDL cholesterol), and 
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higher values of plasma fibrinogen, with similar plasma creatinine levels 
between groups.  
 
Cardiac Geometric and Functional Characteristics by MetS class. 
 After adjustment for age, gender, height and heart rate, LV chamber 
size (diameter), aortic root and left atrial diameter were greater in Mets 
adolescents compared to non-MetS (Table 3). LV mass and RWTa were also 
significantly higher in MetS participants (all p<0.0001). Accordingly, 
prevalence of LA dilatation (63.1 vs 21.9 %) and LV hypertrophy (43.2 vs 
11.7%) were markedly higher in the presence of MetS (both p<0.001). 
Stroke volume and cardiac output were increased in MetS participants, due to 
enlarged LV chamber size. Ejection fraction was similar in the two groups; in 
contrast mid-wall shortening was lower in MetS than in non-MetS 
adolescents. Finally, MetS adolescents exhibited significantly lower transmitral 
E/A ratio and slightly longer deceleration time of E velocity, but no significant 
difference in isovolumic relaxation time. Results were confirmed also when 
applying adult ATPIII criteria for the definition of MetS (data not shown). 
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Predictors of Left Artial Dilatation and Left Ventricular Hypertrophy 
In univariate binary logistic regression, LA dilatation was predicted mainly 
by the presence of obesity (OR=26.26; CI=10.33-66.77; p<0.001) and higher 
systolic blood pressure (OR=1.04; CI=1.02-1.06; p<0.001), and then by 
higher triglycerides (OR=1.01; CI=1.00-1.02; p<0.01) and male gender 
(OR=1.65; CI=1.47-1.77; p<0.01), and negatively by higher HDL cholesterol 
(OR=0.96; CI=0.94-0.98: p<0.01), with no significant impact of fasting 
glucose or age (p=ns). As shown in Table 4a, in hierarchical multivariate 
regression, male gender (OR=3.32; CI=1.80-6.13), obesity (OR=4.17; 
CI=2.62-6.66; both p<0.001) and systolic blood pressure (OR=1.03; 
CI=1.01-1.06; p<0.01), still predicted LA dilatation, with no significant impact 
of age and single metabolic components of the MetS. In contrast, a 
significant effect was observed for clustered MetS, which conferred an 
additional 2.3 fold increased risk of LA dilatation (OR=2.33; CI=1.14-4.73; 
p=0.020), independently of demographics and single components of the 
syndrome.   
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Similar results were also observed for LV hypertrophy. In univariate binary 
logistic analysis, LV hypertrophy was predicted mainly by the presence of 
obesity (OR=12.10; CI=4.29-33.99; p<0.001) and higher systolic blood 
pressure (OR=1.03; CI=1.01-1.06; p<0.001), and then by higher 
triglycerides (OR=1.02; CI=1.01-1.04; p<0.05), and older age (OR=1.19; 
CI=1.01-1.41; p<0.05), and negatively by higher HDL cholesterol (OR=0.96; 
CI=0.94-0.99: p<0.01), with no significant impact of fasting glucose or 
gender (p=ns).  As shown in Table 4b, in hierarchical multivariate regression, 
obesity (OR=2.38; CI=1.41-4.04) and systolic blood pressure (OR=1.04; 
CI=1.01-1.07) still predicted LV hypertrophy (both p<0.01), with no 
significant impact of age, gender and single metabolic components of MetS. 
In contrast, a significant effect was observed for clustered MetS, which 
conferred an additional 2.6 fold increased risk of LV hypertrophy (OR=2.57; 
CI=1.21-5.44; p=0.014), independently of demographics and single 
components of the syndrome.  When adult ATPIII definition was applied, no 
additional independent risk was found for MetS for either LA dilatation or LV 
hypertrophy. 
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Alternative models replacing obesity with waist circumference, and fasting 
glucose with either HOMA-index or insulin did not significantly change the 
reported results.  
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Discussion 
  The present study provides the first evidence of a strong impact of MetS 
on cardiac phenotype in an unselected population of adolescents applying 
criteria for the definition of MetS specifically designed for this age range (23, 
35-37). To our knowledge, only one recent report has attempted to identify 
possible independent impact of MetS on cardiovascular phenotype in 
adolescents and has failed to shown a significant association between MetS 
and intima-media thickness (38).  
In a previous report that analyzed data of the NHANES study, a highly 
representative study of the United States, Goodman et al. described a 4.2% 
prevalence of the MetS in the general adolescent US population, with a 
markedly higher prevalence, reaching 19.5%, in overweight/obese 
adolescents (35), when applying adolescent-ATPIII criteria. The evidence that 
MetS is associated with unfavorable cadiovascular phenotype and unfavorable 
clinical outcome also in the absence of overt hypertension and/or diabetes 
supports the hypothesis that MetS might represent a distinct medical 
condition, at least from an epidemiological point of view (39). The high 
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prevalence of MetS in adults and adolescents has increased medical attention 
on the syndrome (11-12, 35-37), also considering the increased burden of 
obesity and related metabolic complications found in epidemiological surveys 
in different countries (40). 
 In the present study, adolescents with MetS exhibit worrisome 
abnormalities of cardiac geometry and function, including aortic root and LA 
dilatation, a trend towards concentric LV geometry and a remarkable high 
prevalence of LV hypertrophy, present in over 40% of MetS adolescents. 
Furthermore, we found significant impairment in LV wall mechanics and 
diastolic function (as shown by reduced mitral E/A ratio and prolonged E 
wave deceleration time).  Interestingly, the negative effect of MetS on cardiac 
phenotype was independent of the effect of the single risk factors defining 
the syndrome, consistent with the notion that also in adolescents, clustering 
of risk factors in MetS might be predictive of cardiovascular disease above 
and beyond the risk associated with its single components.  
Other authors have reported independent correlations among body size, 
metabolic abnormalities and LV mass growth, in children and adolescents 
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(41-42), but MetS has not yet been considered as a pathologic entity in this 
setting.  The Bogalusa Heart Study reported an association between insulin 
and LV mass growth in obese adolescent girls, also independently of blood 
pressure (43). In the present study multivariate modelling showed that the 
risk of LV hypertrophy and LA dilatation associated with MetS is additional to 
what caused by obesity and blood pressure, while single metabolic risk 
factors are associated to markers of cardiovascular disease only in univariate 
regression.  
It has been recently reported that the prevalence of the MetS varies 
widely in overweight adolescents depending on the proposed definition (44) 
and that the instability in the diagnosis of the MetS in adolescents (caused by 
both gain and loss of the diagnosis) might imply a reduced clinical utility of 
the syndrome (45).  In the present study we have tested, age- and gender-
specific criteria for the definition MetS, proposed with the specific aim of 
minimizing the instability of MetS diagnosis in the adolescent age range 
(23,45). Remarkably, compared to adult definition of MetS, the proposed 
adolescent criteria were able to identify a strong, independent and additional 
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impact of the Mets on cardiac markers of preclinical disease. In addition, 
although follow-up data for the adolescents included in the present analysis 
are not yet available, the significant alteration of CV phenotype identified in 
the presence of MetS strongly suggests that the diagnosis of MetS even 
obtained from a single clinical exam should encourage prompt lifestyle risk-
reducing interventions in otherwise healthy adolescents.  
    
Study limitations 
The present study has been performed on American Indians, a specific 
ethnic group on which adolescent-ATPIII criteria where not specifically tested 
in NHANES. However, in our sample of adolescents with high prevalence of 
obesity, MetS was present in 25% of the population, substantially similar to 
prevalence reported in the NHANES in the obese/overweight US adolescent 
population (35). As suggested by current guidelines for the definition of MetS, 
we have applied waist circumference partition values to identify the presence 
of abdominal obesity, although increasing evidence suggests that a direct 
measure of intra-abdominal fat should be preferred. However, it has been 
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recently shown in a population-based sample of boys and girls that waist 
circumference offers a feasible alternative to the MRI estimation of intra-
abdominal adipose tissue (46). Eventually, determination of Tanner stage was 
not performed, and the relation between body maturation and cardiac 
geometry/function could not be investigated; of note, both LV mass and LA 
diameter were indexed by height, a method that has been previously shown 
to correct for body growth (30); in addition all participants were ≥14 years of 
age and, therefore, the possibility of significant prevalence of pre-pubertal 
participants was minimized. 
 
Conclusions 
In conclusion, in our cohort of adolescents, MetS was associated with a 
strikingly high prevalence of LV hypertrophy and LA dilatation, associated 
with increased aortic root diameter and impairment in both systolic and 
diastolic LV performance. The impact of MetS on cardiac markers of 
preclinical disease appears to be independent and additional to obesity, blood 
pressure and single metabolic abnormalities suggesting that, also in 
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adolescents, the risk associated with MetS might be beyond what is predicted 
by single risk factors. Our findings, paired with previous studies reporting a 
steep increase in the prevalence of obesity and associated metabolic 
abnormalities in children and young adults, suggest that presence of MetS in 
adolescents should prompt aggressive lifestyle modifications to reduce the 
increasing burden of future CV disease. 
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Table 1. Clinical Characteristics of Study Participants with and 
without Metabolic Syndrome. 
 No MetS 
(N=335) 
Mets 
(N=111) 
P 
Age (years) 17.3±1.4 17.6±1.5 0.072 
Women (%) 51.9 55.9 0.511 
Fat free mass (Kg) 50.3±10.6 60.1±14.6 <0.0001 
Adipose mass (Kg) 23.8±14.2 45.8±18.8 <0.0001 
Body mass index (Kg/m2) 25.9±6.4 37.0±8.1 <0.0001 
Systolic BP (mmHg) 111.2±10.4 120.5±11.4 <0.0001 
Diastolic BP (mmHg) 67.8±9.1 75.2±10.0 <0.0001 
Heart rate (bpm’) 64.7±10.5 65.6±11.9 0.312 
Obesity (%) 37.1 92.8 <0.0001 
Hypertension (%) 3.6 16.2 <0.0001 
Cigarette Smoking (%) 22.1 20.3 0.312 
Alcohol drinking (%) 55.2 46.8 0.133 
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Table 2. Metabolic Characteristics of Study Participants with and without 
Metabolic Syndrome. 
 
No MetS 
(N=335) 
Mets 
(N=111) 
P 
Fasting glucose (mg/dl) 89.2±8.4 94.2±8.0 <0.0001
Plasma insulin (IU/ml) 13.2±10.7 28.7±37.2 <0.0001
Log HOMA-index 0.36±0.30 0.70±0.27 <0.0001
Triglycerides (mg/dL) 93.6±43.1 178.0±72.3 <0.0001
Total cholesterol (mg/dL) 149.7±26.7 168.6±27.7 <0.0001
LDL cholesterol (mg/dL) 79.9±23.1 95.1±25.0 <0.0001
HDL cholesterol (mg/dL) 51.3±12.1 40.1±10.1 <0.0001
Fibrinogen (mg/dL) 341.6±76.4 393.3±73.0 <0.0001
Creatinine  (mg/dL) 0.79±0.15 0.77±0.13 0.179 
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Table 3. Cardiac Characteristics of Study Participants with and without 
Metabolic Syndrome. 
 
No MetS 
(N=335) 
Mets 
(N=111) 
P 
Left ventricular diameter (cm) 5.21±0.39 5.38±0.44 0.001 
Aortic root (cm) 3.03±0.25 3.14±0.31 0.001 
Left atrial diameter (cm) 3.31±0.41 3.79±0.35 <0.0001
Left atrial dilatation (%) 21.9 63.1 <0.0001
LV mass (g) 132.3±31.2 157.7±39.1 <0.0001
LV mass index (g/m2.7) 32.0±6.1 38.0±7.2 <0.0001
LV hypertrophy (%) 10.8 41.8 <0.0001
Age adj. relative wall thickness 0.27±0.04 0.29±0.04 <0.0001
Stroke volume (mL) 78.1±14.2 84.9±14.6 <0.0001
Cardiac output (L/min) 5.02±0.99 5.47±1.01 <0.0001
Ejection fraction (%) 59.9±4.4 59.7±4.8 0.612 
Mid-wall shortening (%) 18.9±1.5 18.3±1.7 0.001 
Mitral E/A ratio 1.86±0.45 1.71±0.40 0.001 
E deceleration time (msec) 206.5±36.2 215.9±36.7 0.022 
IVRT (msec) 71.9±8.5 79.9±9.1 0.318 
 
ANCOVA with Sidak’s adjusted means for age, gender, heart rate and height. 
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Table 4a. Hierarchical multivariate regression for Left Atrial Dilatation. 
95.0% C.I.   
  
P OR 
Lower Upper 
Step 1 Age (years) .058 .842 .706 1.006 
  Gender (M) .001 3.322 1.800 6.130 
Step 2 Presence of Obesity .001 4.174 2.617 6.657 
Step 3 Systolic Blood Pressure (mmHg) .015 1.032 1.006 1.059 
Step 4 HDL-C (mg/dL) .171 .985 .965 1.006 
  Fasting Glucose (mg/dL) .644 .992 .960 1.025 
  Tryglycerides (mg/dL) .557 .999 .994 1.003 
Step 5 MetS .020 2.326 1.143 4.734 
OR= odds ratio, C.I = confidence interval. 
Table 4b. Hierarchical multivariate regression for Left Ventricular Hypertrophy. 
95.0% C.I.    
  
P OR 
Lower Upper
Step 1 Age (years) .368 1.093 .900 1.328 
  Gender (M) .518 1.241 .645 2.386 
Step 2 Presence of Obesity .001 2.385 1.408 4.041
Step 3 Systolic Blood Pressure (mmHg) .006 1.041 1.012 1.071
Step 4 HDL-C (mg/dL) .407 .990 .966 1.014 
  Fasting Glucose (mg/dL) .262 .980 .945 1.016 
  Tryglycerides (mg/dL) .946 1.000 .995 1.004 
Step 5 MetS .014 2.565 1.210 5.438
OR= odds ratio, C.I = confidence interval. 
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Appendix 1  
 
a. Partition Values for the Definition of Metabolic Syndrome using modified 
ATPIII criteria. 
 
Gender Waist 
(cm) 
SBP  
(mmHg) or 
DBP 
(mmHg)
HDL-C 
(mmol/L)
Triglycerides 
(mmol/L) 
Glucose 
(mmol/L)
Boys 102 130 85 1.0 1.7 5.6 
Girls 88 130 85 1.3 1.7 5.6 
 
 
b. Partition Values for the Definition of Metabolic Syndrome in Adolescent Boys 
and Girls (according to Jolliffe and Janssen). 
 
BOYS 
AGE 
(years) 
Waist 
(cm) 
SBP  
(mmHg) or
DBP 
(mmHg)
HDL-C 
(mmol/L)
Triglycerides 
(mmol/L) 
Glucose 
(mmol/L)
12 94.2 121 76 1.13 1.44 5.6 
13 96.2 123 78 1.10 1.48 5.6 
14 98.0 125 79 1.07 1.52 5.6 
15 99.5 126 81 1.04 1.56 5.6 
16 100.6 128 82 1.03 1.59 5.6 
17 101.4 128 83 1.03 1.62 5.6 
18 101.8 129 84 1.03 1.65 5.6 
19 102.0 130 85 1.03 1.68 5.6 
20 102.0 130 85 1.03 1.70 5.6 
 
 
GIRLS 
AGE 
(years) 
Waist 
(cm) 
SBP  
(mmHg) or
DBP 
(mmHg)
HDL-C 
(mmol/L)
Triglycerides 
(mmol/L) 
Glucose 
(mmol/L)
12 79.5 121 80 1.25 1.60 5.6 
13 81.3 123 82 1.25 1.53 5.6 
14 82.9 125 83 1.26 1.46 5.6 
15 84.2 126 84 1.26 1.44 5.6 
16 85.2 128 84 1.27 1.46 5.6 
17 86.2 128 85 1.27 1.53 5.6 
18 87.0 129 85 1.28 1.61 5.6 
19 87.7 130 85 1.29 1.68 5.6 
20 88.0 130 85 1.30 1.70 5.6 
 
 
 
